You can buy or sell ITCI and other stocks, options, ETFs, and crypto commission-free!
Intra-Cellular Therapies Inc. Common Stock, also called Intra-Cellular Therapies, is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Read More Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMay 8
Intra-Cellular Therapies Inc. (ITCI) CEO Sharon Mates on Q1 2019 Results - Earnings Call Transcript
Intra-Cellular Therapies, Inc (NASDAQ:ITCI) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Juan Sanchez – Vice President of Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Executive Vice President and Chief Commercial Officer Andrew Satlin – Executive Vice President and Chief Medical Officer Larry Hineline – Senior Vice President and Chief Financial Officer Kimberly Vanover – Senior Vice President of Early Stage Clinical Development ...
Yahoo FinanceMay 8
Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow.
Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019, and provided a corporate update. "2018 was an important year for ITCI and our momentum has carried over into 2019," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "Our NDA for lumateperone for the ...
Expected Aug 1, Pre-Market